Endoscopic Resection Multicenter Registry
Endoscopic Resection: A Retrospective and Prospective Multicenter Registry
This is a retrospective and prospective multicenter registry to collect long-term data (1 year) on patients who have or will undergo Endoscopic resection such as EMR, ESD, EFTR, STER, etc. within the gastrointestinal tract for endoscopic treatment of early gastrointestinal neoplasms involving the resection of the superficial layers, mucosa and submucosa, of the tract wall.
Subjects will be consented for medical chart review.
The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of Endoscopic Resection within the gastrointestinal tract (1 year).
The registry will evaluate efficacy, technical feasibility, clinical outcome, safety profile and overall clinical management through medical chart review. The procedures the investigators are evaluating are all clinically indicated and will not be prescribed to someone to participate in this registry study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Endoscopic resection can be an appropriate approach in early neoplasms, challenging adenomas or sub-epithelial lesions. Endoscopic resection can be considered as a less invasive approach than surgery. Moreover, endoscopic resection can be available to patients who are ineligible for surgery or who have refused more aggressive surgical intervention.
The study investigators would collect data on a large sample size of subjects undergoing various endoscopic resection procedures such as EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection, and EFTR (Endoscopic full-thickness resection). Clinical metrics will be recorded including procedure times, length of follow-up, specific tumor characteristics, resection method, pathology results, procedural complications, additional therapy required, and disease-free survival time.
Currently, there is limited multi-center data on endoscopic resection outcomes in western populations.
Evaluation of these measurement would help the investigators compare them to conventional treatment modalities within current tertiary facilities; and consequently help the investigators identify appropriate treatment techniques and improve clinical management of patients at WCMC-NYPH.
The purpose of this retrospective and prospective registry is to assess long term data on efficacy, safety and clinical outcome of Endoscopic Resection within the gastrointestinal tract (1 year).
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient who is considering undergoing endoscopic resection within 6 months, or has undergone clinically indicated endoscopic resection within the past 6 months
- Above or equal to 18 years of age.
Exclusion Criteria:
- Any patient who has not undergone or will undergo endoscopic resection
- Below 18 years of age.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Endoscopic Resection
Patients undergoing Endoscopic Resection
|
Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with reduction in clinical symptoms
Time Frame: 6 months from procedure
|
To assess resolution of symptoms of all Endoscopic resection procedures at 6 months
|
6 months from procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 30 days post procedure
|
Number of subjects with Adverse Events; Type, frequency and intensity of adverse events within 30 days of procedure
|
30 days post procedure
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with successful completion of treatment
Time Frame: 30 days post procedure
|
Number of participants with successful completion of treatment
|
30 days post procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Stomach Diseases
- Head and Neck Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Intestinal Neoplasms
- Esophageal Diseases
- Duodenal Diseases
- Colorectal Neoplasms
- Neoplasms
- Stomach Neoplasms
- Gastrointestinal Diseases
- Digestive System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Polyps
- Esophageal Neoplasms
- Colonic Neoplasms
- Duodenal Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- 1701017930
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
NCT07331532RecruitingBreast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
-
NCT07428213Not yet recruiting
-
NCT07173985RecruitingColonic Neoplasms
-
NCT06338332RecruitingColonic Neoplasms Malignant
-
NCT00985036WithdrawnGlioma | Meningioma
-
NCT07557212Not yet recruiting
-
NCT00179881CompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain Stem
Clinical Trials on Endoscopic Resection
-
NCT05428553Recruiting
-
NCT05452265CompletedGastric Subepithelial Tumor
-
NCT05825664RecruitingColorectal Neoplasms | Colorectal Polyp
-
NCT02935049UnknownColorectal Adenoma | Intramucinous Adenocarcinoma
-
NCT01105728CompletedGastric Subepitelial Mass
-
NCT03021135CompletedColorectal Neoplasms | Adenoma
-
NCT02198729Completed
-
NCT02583087UnknownBarrett Esophagus | Esophageal Neoplasm
-
NCT01726907WithdrawnSMG Resection in Comparison to Endoscopic SMG Resection